• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

非小细胞肺癌脑转治疗方法荟萃(更新于2011年11月9日)

    [复制链接]
1102615 492 老马 发表于 2011-10-15 20:30:11 |
rong303030  高中二年级 发表于 2014-2-14 10:05:56 | 显示全部楼层 来自: 湖北咸宁
好贴,学习中
rong303030  高中二年级 发表于 2014-2-14 13:17:15 | 显示全部楼层 来自: 湖北咸宁
老马 发表于 2012-5-30 01:08
中医根据咳嗽的不同表征,将咳嗽分为5种类型。 风寒咳嗽:吐稀痰,伴有头痛、鼻塞、流清涕、怕冷及发烧;风 ...

我妈就是脑转发展时颧骨发红,吃凯美纳后碱经,用中医怎么解释呢
父亲患癌去世多年,只求多留母亲两年。
huanzi  大学二年级 发表于 2014-2-24 21:30:17 | 显示全部楼层 来自: 中国
特罗凯控制脑转8个月,4002二个月,准备放疗,应注意什么?病友们,老师们告诫一下,止吐药叫什么名字,口里需含蜂蜜吗?急需!!
马太福音9:29照着你们的信给你们成全了吧。!

举报 使用道具

回复 支持 0 反对 1
huanzi  大学二年级 发表于 2014-2-24 21:31:20 | 显示全部楼层 来自: 中国
特罗凯控制脑转8个月,4002二个月,准备放疗,应注意什么?病友们,老师们告诫一下,止吐药叫什么名字,口里需含蜂蜜吗?急需!!
马太福音9:29照着你们的信给你们成全了吧。!

举报 使用道具

回复 支持 0 反对 1
累计签到:2 天
连续签到:1 天
[LV.1]初来乍到
chenhongyu  高中二年级 发表于 2014-3-30 21:27:19 | 显示全部楼层 来自: 江苏扬州
脑转的概率多大?手术后靶向药能控制吗?CT和CEA正常的情况下也会发生脑转吗?

点评

会的,我就是血检,胸部CT正常发现脑转的,现在服特罗凯,症状消失,不过医生说20%的比例对脑部有效  发表于 2014-11-12 19:20

举报 使用道具

回复 支持 0 反对 1
guoguo0591  初中一年级 发表于 2014-3-30 22:23:39 | 显示全部楼层 来自: 福建福州
感谢版主资料。

举报 使用道具

回复 支持 0 反对 1
weimj321  高中二年级 发表于 2014-7-10 16:44:38 | 显示全部楼层 来自: 江苏苏州
升升不息 发表于 2011-10-15 21:43
我也觉得全脑放比较妥当,但是时机选择非常重要。看吴娱的帖子,她了解脑转移的很多病人,最后生存期长的无 ...

在没有发生脑转之前需要做预防性的全脑放射治疗吗?听说全脑放只能做一次,是吗?

举报 使用道具

回复 支持 0 反对 1
hengkong  小学六年级 发表于 2014-7-13 21:41:58 | 显示全部楼层 来自: 中国
这个帖子的含金量很高。我们家的头痛一个多月了,PET-CT未查出脑部有变化,加强核磁诊断疑似脑转。已经开始服用替莫唑胺,40mg服用5天,200mg服用5天,不知有无效果。

举报 使用道具

回复 支持 0 反对 1
阿Q  大学二年级 发表于 2014-7-15 13:01:03 | 显示全部楼层 来自: 上海南汇区
老马 发表于 2013-12-13 12:14
罗氏的Brain Shuttle技术
http://www.roche.com/research_and_development/what_we_are_working_on/resear ...

http://www.reuters.com/article/2 ... USBREA070ZY20140108

(Reuters) - Swiss drugmaker Roche has found an efficient way for complex antibody drugs to reach and penetrate the brain, raising the possibility of more effective treatments for diseases such as Alzheimer's.

The innovative brain shuttle technology, which has so far been tested in mice, can cross the blood-brain barrier that has been a key obstacle for researchers working on neurological drugs because it acts as a seal against large molecules such as antibodies.

Alzheimer's is a fatal brain-wasting disease that affects 44 million people worldwide, with the number set to triple by 2050, campaign group Alzheimer's Disease International says.

Although there is still no treatment that can effectively modify the disease or slow its progression, a number of companies - including Roche, Eli Lilly, Merck & Co and Johnson & Johnson - are pursuing a variety of approaches to get to the root cause.

It is proving an uphill battle. Over the past 15 years more than 100 experimental Alzheimer's drugs have failed in tests. Industry analysts believe that the prize for a truly effective drug could be a market worth $10 billion in annual sales.

Roche's new technology works by hijacking a natural transport mechanism called receptor-mediated transcytosis, which is normally used by the body to transfer proteins inside the brain.

"We have basically designed this module, called shuttle, that binds to this transport mechanism and shuttles a cargo inside the brain," Luca Santarelli, Roche's head of neuroscience, ophthalmology and rare diseases, said in a telephone interview.

ANTIBODY BOOST

Results of a study published in the journal Neuron on Wednesday found the technology helped to increase the concentration of antibodies in the brains of mice, reducing the amount of amyloid plaque, which is a hallmark of Alzheimer's.

Roche tested a precursor of its experimental Alzheimer's drug gantenerumab in the pre-clinical trials. The amount of antibody that penetrated the brain increased more than fiftyfold.

Santarelli said that the brain shuttle technology is not limited to the memory-robbing disease and could be applied to other neurodegenerative disorders such as Huntington's disease. The drugmaker is in the process of evaluating which therapeutic targets and diseases to prioritize.

Roche has struck a deal with U.S. biotech firm Isis to develop treatments for Huntington's and aims to engineer a shuttle to increase penetration of drugs into the brain. It is also working on a program with Irish company Prothena in Parkinson's disease.

Santarelli said that all projects are still in pre-clinical testing and the company needs to undertake a few more steps before it can begin clinical trials.

Turning to Roche's Alzheimer's pipeline, he said that its Phase III trial of gantenerumab in patients who have yet to develop dementia is on track, with results expected in the first half of 2016.

Roche has two other drugs in clinical testing, including crenezumab, which has been chosen for a U.S. government-backed trial in a group of Colombians with a genetic mutation that leads to Alzheimer's in their forties.

举报 使用道具

回复 支持 0 反对 1
huanzi  大学二年级 发表于 2014-7-20 18:32:41 | 显示全部楼层 来自: 中国
我多发脑转,经过15次4000GY的放疗,二月后复查,还是多发,由于身体不耐受,跌了20多斤,大夫说受不了化疗,有的大夫让我做伽马刀,时间太短了,病友们谁有和我一样,去做过伽马刀?
马太福音9:29照着你们的信给你们成全了吧。!

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表